Chloroquine for the 2019 novel coronavirus SARS-CoV-2.
作者信息
Colson Philippe, Rolain Jean-Marc, Raoult Didier
机构信息
Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
出版信息
Int J Antimicrob Agents. 2020 Mar;55(3):105923. doi: 10.1016/j.ijantimicag.2020.105923. Epub 2020 Feb 15.
Abstract
摘要
相似文献
1
Chloroquine for the 2019 novel coronavirus SARS-CoV-2.氯喹用于2019新型冠状病毒SARS-CoV-2。
Int J Antimicrob Agents. 2020 Mar;55(3):105923. doi: 10.1016/j.ijantimicag.2020.105923. Epub 2020 Feb 15.
2
The novel zoonotic COVID-19 pandemic: An expected global health concern.新型人畜共患的新冠疫情：一个意料之中的全球卫生问题。
J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671.
3
SARS-CoV-2 Does Not Replicate in Aedes Mosquito Cells nor Present in Field-Caught Mosquitoes from Wuhan.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）不在伊蚊细胞中复制，也不存在于从武汉采集的野外蚊子体内。
Virol Sin. 2020 Jun;35(3):355-358. doi: 10.1007/s12250-020-00251-0. Epub 2020 Jun 29.
4
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
5
Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection.用假型化严重急性呼吸综合征冠状病毒（SARS-CoV）处理的小鼠血清中和2019新型冠状病毒（2019-nCoV）感染的低效性
Virol Sin. 2020 Jun;35(3):340-343. doi: 10.1007/s12250-020-00214-5. Epub 2020 Mar 31.
6
Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2).传统中药是针对2019新型冠状病毒（SARS-CoV-2）进行药物研发的资源。
J Integr Med. 2020 Mar;18(2):87-88. doi: 10.1016/j.joim.2020.02.004. Epub 2020 Feb 19.
7
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
8
Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.新型冠状病毒肺炎、严重急性呼吸综合征和中东呼吸综合征的生物学、临床和流行病学特征，以及 ACE2 的 AutoDock 模拟
Infect Dis Poverty. 2020 Jul 20;9(1):99. doi: 10.1186/s40249-020-00691-6.
9
[Structure of SARS-CoV-2 and treatment of COVID-19].[严重急性呼吸综合征冠状病毒2的结构与冠状病毒病的治疗]
Sheng Li Xue Bao. 2020 Oct 25;72(5):617-630.
10
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.氯喹和羟氯喹在2019冠状病毒病中的应用：对医疗保健专业人员的实践启示
J Coll Physicians Surg Pak. 2020 Oct;30(10):124-128. doi: 10.29271/jcpsp.2020.supp2.124.
引用本文的文献
1
Nasal inhalation of antiviral microparticulate powders to target early infection of upper airways.经鼻腔吸入抗病毒微粒粉末以靶向治疗上呼吸道早期感染。
Drug Deliv Transl Res. 2025 Jul 15. doi: 10.1007/s13346-025-01916-7.
2
[Recommendations for rheumatologists on pharmacological management during the COVID-19 health emergency: Expert group opinion].[COVID-19 健康紧急状态下风湿病学家药物治疗管理建议：专家组意见]
Rev Colomb Reumatol. 2021 Apr-Jun;28(2):134-140. doi: 10.1016/j.rcreu.2020.05.021. Epub 2020 Jun 26.
3
Herbal Medicines as Complementary Therapy for Managing Complications in COVID-19 Patients with Diabetes Mellitus.草药作为管理2型糖尿病合并新冠患者并发症的辅助疗法
Diabetes Metab Syndr Obes. 2025 Jan 16;18:135-146. doi: 10.2147/DMSO.S498774. eCollection 2025.
4
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.COVID-19治疗潜在药物和疫苗的临床前与临床研究：近期更新的综合综述
Clin Pathol. 2024 Jul 26;17:2632010X241263054. doi: 10.1177/2632010X241263054. eCollection 2024 Jan-Dec.
5
Potential Therapeutic Options for COVID-19.2019冠状病毒病的潜在治疗选择
Infect Microbes Dis. 2020 Jul 16;2(3):89-95. doi: 10.1097/IM9.0000000000000033. eCollection 2020 Sep.
6
A narrative review on adverse drug reactions of COVID-19 treatments on the kidney.关于新冠病毒疾病治疗药物对肾脏不良反应的叙述性综述。
Open Med (Wars). 2024 Mar 15;19(1):20230867. doi: 10.1515/med-2023-0867. eCollection 2024.
7
Global prevalence of persistent neuromuscular symptoms and the possible pathomechanisms in COVID-19 recovered individuals: A systematic review and meta-analysis.新冠康复者中持续性神经肌肉症状的全球患病率及可能的发病机制：一项系统综述和荟萃分析
Narra J. 2021 Dec;1(3):e48. doi: 10.52225/narra.v1i3.48. Epub 2021 Dec 1.
8
potently inhibits the activity of SARS-CoV-2 3CL protease.有效抑制新型冠状病毒3CL蛋白酶的活性。
Biochem Biophys Rep. 2023 Dec 26;37:101626. doi: 10.1016/j.bbrep.2023.101626. eCollection 2024 Mar.
9
The Penn Medicine COVID-19 Therapeutics Committee-Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency.宾夕法尼亚大学医学部新冠治疗委员会——关于公共卫生紧急事件期间快速证据审查及动态实践建议模式的思考
Open Forum Infect Dis. 2023 Aug 9;10(8):ofad428. doi: 10.1093/ofid/ofad428. eCollection 2023 Aug.
10
Prediction of tsunami of resistance to some antibiotics is not far-fetched which used during COVID-19 pandemic.预测在新冠疫情期间使用的某些抗生素出现耐药性海啸并非牵强之事。
J Clin Lab Anal. 2023 Aug;37(15-16):e24959. doi: 10.1002/jcla.24959. Epub 2023 Aug 31.
本文引用的文献
1
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
2
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
3
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.冠状病毒对抗病毒药物瑞德西韦（GS-5734）的易感性是由病毒聚合酶和校对核糖核酸外切酶介导的。
mBio. 2018 Mar 6;9(2):e00221-18. doi: 10.1128/mBio.00221-18.
4
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.药物研发中的氯喹类似物：从疟疾到多种疾病的新应用方向、作用机制及毒性表现
J Antimicrob Chemother. 2015;70(6):1608-21. doi: 10.1093/jac/dkv018. Epub 2015 Feb 17.
5
Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.对一个经美国食品药品监督管理局批准的化合物文库进行筛选，鉴定出四种在细胞培养中可抑制中东呼吸综合征冠状病毒复制的小分子抑制剂。
Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84. doi: 10.1128/AAC.03011-14. Epub 2014 May 19.
6
Severe acute respiratory syndrome beyond Amoy Gardens: completing the incomplete legacy.淘大花园之外的严重急性呼吸综合征：完善未竟之业。
Clin Infect Dis. 2014 Mar;58(5):683-6. doi: 10.1093/cid/cit797. Epub 2013 Dec 6.
7
Malaria.疟疾。
Lancet. 2014 Feb 22;383(9918):723-35. doi: 10.1016/S0140-6736(13)60024-0. Epub 2013 Aug 15.
8
Drug repurposing programmes get lift off.药物重新利用项目启动。
Nat Rev Drug Discov. 2012 Jun 29;11(7):505-6. doi: 10.1038/nrd3776.
9
The role of antimalarial agents in the treatment of SLE and lupus nephritis.抗疟药物在治疗系统性红斑狼疮和狼疮性肾炎中的作用。
Nat Rev Nephrol. 2011 Oct 18;7(12):718-29. doi: 10.1038/nrneph.2011.150.
10
Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century.氯喹及其羟基类似物的再利用以应对21世纪的细菌、真菌和病毒感染。
Int J Antimicrob Agents. 2007 Oct;30(4):297-308. doi: 10.1016/j.ijantimicag.2007.05.015. Epub 2007 Jul 16.
Zotero 插件